<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9927">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05687344</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00046214</org_study_id>
    <nct_id>NCT05687344</nct_id>
  </id_info>
  <brief_title>Intensive Postpartum Antihypertensive Treatment</brief_title>
  <acronym>IPAT</acronym>
  <official_title>Intensive Postpartum Antihypertensive Treatment to Improve Women's Cardiovascular Health (IPAT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-term goal of our work is to evaluate the effect of intensive postpartum blood&#xD;
      pressure control on maternal cardiovascular health, risk of chronic hypertension, and&#xD;
      reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus&#xD;
      attenuating the lifelong trajectory of cardiovascular disease risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IPAT will randomize 60 postpartum patients with HDP at the Medical College of Wisconsin&#xD;
      (MCW) to intensive BP control with Nifedipine extended release (ER) (target BP &lt;140/90 mmHg)&#xD;
      versus usual care (target BP &lt;160/110 mmHg). Oversampling of Black patients with HDP will be&#xD;
      done to ensure they comprise 50% of study participants. Patients enrolled in both arms will&#xD;
      undergo education on healthy lifestyle following AHA &quot;Life's Essential 8&quot; (LE8) of tobacco&#xD;
      cessation, physical activity, healthy sleep, and healthy diet with detailed overview of DASH&#xD;
      throughout the first year postpartum with monthly virtual educational session delivered by a&#xD;
      registered dietician and a life coach. Assessment of LE8 CVH score will be done after&#xD;
      delivery, 6 weeks postpartum, and 12 months postpartum. Participants will also undergo&#xD;
      vascular function assessment: endothelial dysfunction with brachial artery flow mediated&#xD;
      dilation (FMD), arterial stiffness with carotid-femoral pulse wave velocity (cfPWV) and&#xD;
      anti-angiogenic and inflammatory CVD biomarker with soluble fms-like tyrosine kinase&#xD;
      (sFlt-1), at baseline, 6 weeks, and 12 months postpartum. The primary outcome is feasibility&#xD;
      of all study procedures, including recruitment, retention, and adherence. Secondary outcomes&#xD;
      are change in BP, CVH score, FMD, PWV, and sFlt-1 from baseline to 12 months postpartum.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2023</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility in randomization</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Proportion of patients who enroll out of all approached, eligible patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility in recruitment</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Number of patients successfully enrolled per month during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility in retention</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Proportion of enrolled patients who complete all study visits during the 12 months follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contamination</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Percent of patients following other antihypertensive treatment regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New stage I hypertension</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>BP of ≥130/80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life's Essential 8 cardiovascular health score (range 0-100)</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>The score will be calculated using American Heart Association application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life's Simple 7 CVH (range 0-14)</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Same metrics as LE8 excluding sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated dilation</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Brachial artery flow-mediated dilation will assess endothelial dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biomarkers of CVD risk</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Anti-angiogenic marker: Soluble fms-like tyrosine kinase (sFlt-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial stiffness</measure>
    <time_frame>12 months postpartum</time_frame>
    <description>Carotid-femoral pulse wave velocity will assess arterial stiffness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertensive Disorder of Pregnancy</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group - intensive postpartum BP control with Nifedipine initiation at SBP≥140 mmHg or DBP≥90 mmHg and maintaining BP at &lt;140/90 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active control group - a group of usual care that follows ACOG recommendations2 with Nifedipine initiation at SBP≥160 mmHg or DBP≥110 mm Hg and maintaining BP at &lt;160/110 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIFEdipine ER</intervention_name>
    <description>Postpartum BP treatment to &lt;140/90 mmHg</description>
    <arm_group_label>Active control arm</arm_group_label>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Tight BP control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HDP diagnosis (gestational hypertension or preeclampsia) according to ACOG guidelines&#xD;
&#xD;
          -  Postpartum day 0-3 and prior to discharge&#xD;
&#xD;
          -  Able to communicate in English or in Spanish&#xD;
&#xD;
          -  Age 18 - 45&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-gestational hypertension&#xD;
&#xD;
          -  Pre-gestational diabetes ( type 1 or type 2)&#xD;
&#xD;
          -  Intent to transfer postpartum to an outside institution of the participating centers&#xD;
&#xD;
          -  Known allergy to nifedipine or other significant contraindication to nifedipine&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Palatnik, MD</last_name>
    <phone>4148056627</phone>
    <email>apalatnik@mcw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanna Kessel</last_name>
    <phone>4148051124</phone>
    <email>jkessel@mcw.edu</email>
  </overall_contact_backup>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 1, 2023</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 16, 2023</last_update_submitted>
  <last_update_submitted_qc>January 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Anna Palatnik, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

